noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

General Atomics

Timothy Neetz Joins General Atomics as Senior Director of Remote Space[...]
Southeast Missouri State University

SEMO Offers Chance at $1,000 Scholarship for Early FAFSA Completion
Missouri Office of Attorney General

Attorney General Hanaway Warns Missourians Identity Theft Is On The Rise

Healthcare

Genentech Inc.

01/26/2026 | Press release | Distributed by Public on 01/27/2026 00:12

Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity

Read this content

Click here to read the original version at the source's official website. The text of this article is not available at the moment.

Genentech Inc. published this content on January 26, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 27, 2026 at 06:12 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back